Take a look through some of the notable data presentations at this year's ESMO Congress.
Feature|Articles|August 13, 2025
- Vol 53 No 08
- Volume 53
- Issue 08
What should the adult urologist know about pediatric urologic cancers?
Author(s)Jonathan Walker, MD, Amanda Buchanan, MD
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"Pediatric-type cancer diagnoses in adults are rare, and there are important differences in caring for children with genitourinary malignancies compared with adults," write the authors.
Advertisement
Advertisement
Fortunately for patients and families, pediatric urologic oncology is a relatively small component of both pediatric urology and pediatric oncology practice. Despite the rarity of these diagnoses, there is an important role that both the pediatric and adult urologist can play in the management of kidney,
Related to this article
Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Advertisement
Advertisement